DCF Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

DCF Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,800	Closed	-$124K	–	81
2019 Q4	$124K	Buy	+14,800	New	+$136K	0.08%	67

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCF Advisers's SGMO Position: Q3 2021 in Review

DCF Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 13,100 shares — an estimated $157K sold.

DCF Advisers first reported a position in SGMO in Q4 2019 and held it in 7 quarters. The position peaked at $631K in Q2 2020. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

DCF Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
DCF Advisers sold 13,100 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $157K.
DCF Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 7 quarters.
DCF Advisers's SANGAMO THERAPEUTICS INC position peaked at $631K in Q2 2020.
193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on DCF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.